Clinical Trial Protocol for the Combined Use of VAG in the Treatment of ND-AML

This is a clinical efficacy study evaluating the VAG regimen in the treatment of newly diagnosed acute myeloid leukemia (AML). The main objectives of the study are to assess the efficacy and safety of the VAG regimen and to explore the synergistic mechanisms of VAG in combating AML.

Trial Details

NCT ID
NCT06536010
Phase
NA
Sponsor
Yang Xiaotian
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Venetoclax 100 mg d1,200 mg d2,400 mg d3-28;
Locations (sample)
  • Huai'an, Jiangsu, China|33.58861,119.01917

Key Eligibility Criteria

  • Age between 18 and 75 years, regardless of gender.
  • Diagnosis of AML (excluding APL) according to the 2022 World Health Organization (WHO) diagnostic criteria.
  • ECOG performance status of 0-2.
  • For female participants of childbearing potential or male participants with female partners of childbearing potential, effective contraceptive meas…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →